The Mulago Hospital Acting Executive Director Dr. Rosemary Byanyima said that MUJHU comes in to fill the research gap as the hospital gets buried in a huge task of clinical care for patients.
URN spoke to Luke Jerram, an Installation Artist involved in the campaign and he said he chose to use fashion design to illustrate that just as clothing protects us from the outside world, whether from extreme temperature, rain or abrasion, so vaccinations create a layer of protection from infection.
Raltegravir, an integrase inhibitor, is used by people living with HIV that are on third-line treatment. It is administered as a tablet, chewable tablet, and as granules for oral suspension, prescribed for decreasing chances of developing Acquired Immunodeficiency Syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.
This study will be conducted in four districts of Mityana, Masaka, Hoima and Kalangala for a period of six years. According to Dr. Flavia Matovu Kiweewa, a Researcher based at the Makerere University -Johns Hopkins University Research Collaboration, participants will be receiving an injection every after six months.
